Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira® in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis

NCT02714322 is registered in ClinicalTrials.gov with Mylan Inc. as lead sponsor.

NCT NCT02714322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02714322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira® in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis
Lead sponsor
Mylan Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2015
Completion date
March 31, 2017
Enrollment
294 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic, psoriasis